Piramal Pharma Limited has successfully completed the acquisition of an additional 40.67% equity stake in Yapan Bio Private Limited for a total cash consideration of approximately ₹76 crores. With this transaction, the company’s total shareholding in Yapan increased from 33.33% to 74.00%, transforming it from an associate company into a subsidiary.

Yapan Bio Private Limited, incorporated in 2019, operates as a specialized Contract Development and Manufacturing Organization (CDMO) providing process development, characterization, and Phase I/II GMP manufacturing services for advanced biologics and vaccines. Its operational revenue was recorded at ₹26.91 crores in FY2024, ₹54.40 crores in FY2025, and ₹26.34 crores in FY2026.

Operating as a prominent global pharmaceuticals and wellness entity, Piramal Pharma Limited manages its operations through key segments including Contract Development and Manufacturing Solutions (CDMO), Complex Hospital Generics (CHG), and Consumer Healthcare (ICH). In 2025, the company expanded its international manufacturing capabilities, such as investing in payload-linker platforms and facility upgrades across North America and Europe, while maintaining robust regulatory compliance and quality track records.

During FY2025, Piramal Pharma posted a consolidated revenue of ₹9,151 crores, reflecting a 12% year-on-year growth compared to the previous fiscal year. The full-year EBITDA reached ₹1,580 crores with a 15% year-on-year increase, driven by improved operating leverage and cost optimization initiatives. Institutional and public investors hold stakes in the company as part of its publicly traded equity profile on Indian stock exchanges.